When it comes to executive compensation in the biotech and pharma sectors, it pays to be CEO of Regeneron Pharmaceuticals.
The company’s chief executive, Len Schleifer, took home $453 million in 2021, more than any other executive in the sector, according to a STAT analysis. That amount represents just less than the entire combined compensation — $478 million — of the next nine highest-paid biotech and pharma CEOs.
Tim Walbert, CEO of Horizon Therapeutics, took home $70 million last year, the second most among biopharma CEOs. Rounding out the top five: BridgeBio Pharma’s Neil Kumar ($63 million), Intellia Therapeutics’ John Leonard ($54 million), and Clay Siegall, the recently departed CEO of Seattle Genetics ($53.5 million).
About the Author Reprints
Create a display name to comment
This name will appear with your comment
